Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 308

1.

Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease.

Burn D, Emre M, McKeith I, De Deyn PP, Aarsland D, Hsu C, Lane R.

Mov Disord. 2006 Nov;21(11):1899-907.

PMID:
16960863
2.

Effects of rivastigmine in Alzheimer's disease patients with and without hallucinations.

Cummings J, Emre M, Aarsland D, Tekin S, Dronamraju N, Lane R.

J Alzheimers Dis. 2010;20(1):301-11. doi: 10.3233/JAD-2010-1362.

PMID:
20164585
3.

Rivastigmine versus placebo in hyperhomocysteinemic Parkinson's disease dementia patients.

Barone P, Burn DJ, van Laar T, Hsu C, Poewe W, Lane RM.

Mov Disord. 2008 Aug 15;23(11):1532-40. doi: 10.1002/mds.21997.

PMID:
18581467
4.

Rivastigmine for dementia associated with Parkinson's disease.

Emre M, Aarsland D, Albanese A, Byrne EJ, Deuschl G, De Deyn PP, Durif F, Kulisevsky J, van Laar T, Lees A, Poewe W, Robillard A, Rosa MM, Wolters E, Quarg P, Tekin S, Lane R.

N Engl J Med. 2004 Dec 9;351(24):2509-18.

5.

Long-term benefits of rivastigmine in dementia associated with Parkinson's disease: an active treatment extension study.

Poewe W, Wolters E, Emre M, Onofrj M, Hsu C, Tekin S, Lane R; EXPRESS Investigators.

Mov Disord. 2006 Apr;21(4):456-61.

PMID:
16229010
6.

Rivastigmine in dementia associated with Parkinson's disease and Alzheimer's disease: similarities and differences.

Emre M, Cummings JL, Lane RM.

J Alzheimers Dis. 2007 Jul;11(4):509-19. Review.

PMID:
17656830
7.
8.

Rivastigmine transdermal patch and capsule in Alzheimer's disease: influence of disease stage on response to therapy.

Farlow MR, Grossberg GT, Meng X, Olin J, Somogyi M.

Int J Geriatr Psychiatry. 2011 Dec;26(12):1236-43. doi: 10.1002/gps.2669. Epub 2010 Dec 23.

PMID:
22068922
9.

Cholinesterase inhibitors for Parkinson's disease dementia.

Maidment I, Fox C, Boustani M.

Cochrane Database Syst Rev. 2006 Jan 25;(1):CD004747. Review.

PMID:
16437494
10.
11.

A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease--rivastigmine patch versus capsule.

Winblad B, Cummings J, Andreasen N, Grossberg G, Onofrj M, Sadowsky C, Zechner S, Nagel J, Lane R.

Int J Geriatr Psychiatry. 2007 May;22(5):456-67.

PMID:
17380489
12.

Rivastigmine in Alzheimer's disease and Parkinson's disease dementia: an ADAS-cog factor analysis.

Weintraub D, Somogyi M, Meng X.

Am J Alzheimers Dis Other Demen. 2011 Sep;26(6):443-9. doi: 10.1177/1533317511424892. Epub 2011 Oct 18.

PMID:
22009228
13.

Response to rivastigmine or donepezil in Alzheimer's patients with symptoms suggestive of concomitant Lewy body pathology.

Touchon J, Bergman H, Bullock R, Rapatz G, Nagel J, Lane R.

Curr Med Res Opin. 2006 Jan;22(1):49-59. Erratum in: Curr Med Res Opin. 2006 Aug;22(8):1451.

PMID:
16393430
14.

Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period.

Bullock R, Touchon J, Bergman H, Gambina G, He Y, Rapatz G, Nagel J, Lane R.

Curr Med Res Opin. 2005 Aug;21(8):1317-27.

PMID:
16083542
15.

Rivastigmine in the treatment of dementia associated with Parkinson's disease: effects on activities of daily living.

Olin JT, Aarsland D, Meng X.

Dement Geriatr Cogn Disord. 2010;29(6):510-5. doi: 10.1159/000305100. Epub 2010 Jun 5.

PMID:
20523050
16.

Rivastigmine and Parkinson dementia complex.

Moretti R, Torre P, Vilotti C, Antonello RM, Pizzolato G.

Expert Opin Pharmacother. 2007 Apr;8(6):817-29.

PMID:
17425477
17.

Evaluating rivastigmine in mild-to-moderate Parkinson's disease dementia using ADAS-cog items.

Schmitt FA, Aarsland D, Br√łnnick KS, Meng X, Tekin S, Olin JT.

Am J Alzheimers Dis Other Demen. 2010 Aug;25(5):407-13. doi: 10.1177/1533317510367486. Epub 2010 Apr 14.

PMID:
20392860
18.

Efficacy, safety and tolerability of rivastigmine capsules in patients with probable vascular dementia: the VantagE study.

Ballard C, Sauter M, Scheltens P, He Y, Barkhof F, van Straaten EC, van der Flier WM, Hsu C, Wu S, Lane R.

Curr Med Res Opin. 2008 Sep;24(9):2561-74. doi: 10.1185/03007990802328142 . Epub 2008 Jul 31.

PMID:
18674411
19.

Donepezil in Parkinson's disease dementia: a randomized, double-blind efficacy and safety study.

Dubois B, Tolosa E, Katzenschlager R, Emre M, Lees AJ, Schumann G, Pourcher E, Gray J, Thomas G, Swartz J, Hsu T, Moline ML.

Mov Disord. 2012 Sep 1;27(10):1230-8. doi: 10.1002/mds.25098. Epub 2012 Aug 22.

PMID:
22915447
20.

Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease.

Rolinski M, Fox C, Maidment I, McShane R.

Cochrane Database Syst Rev. 2012 Mar 14;(3):CD006504. doi: 10.1002/14651858.CD006504.pub2. Review.

PMID:
22419314

Supplemental Content

Support Center